SynthesisFrontiers in pharmacology2026
Systematic review and meta-analysis of the antidepressant-like effects of ginsenosides in animal models: comparative behavioral profiles and exploratory dose-stratified analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study systematically evaluated the antidepressant-like effects of individual ginsenoside monomers and total ginsenosides in animal models of depression, compared pooled behavioral profiles across components, and summarized the principal mechanisms proposed in the included studies. The comparative analyses were intended to identify patterns within the existing evidence base rather than to establish a definitive hierarchy of antidepressant potency. Methods: Animal studies comparing a ginsenoside intervention with a vehicle-treated depression-model control were synthesized using random-effects meta-analysis. Standardized mean differences (SMDs) were calculated for the sucrose preference test (SPT), forced swim test (FST), tail suspension test (TST), and open field test (OFT) outcomes. Interaction analyses were used to explore component-by-behavior differences, and dose-stratified analyses of ginsenoside Rb1 (GRb1) were considered exploratory. Results: Twenty-five animal studies evaluating 10 individual ginsenoside monomers and total ginsenosides were included. Ginsenoside treatment increased sucrose consumption in the SPT (SMD: 3.20, 95% CI: 2.61-3.80; Z = 10.52; Conclusion: Ginsenosides were associated with improvements across several depression-related behavioral domains in animal models. The evidence supports further investigation of GRb1 and other active monomers in standardized, adequately powered, head-to-head preclinical studies. It does not establish the superiority of one ginsenoside, clinical antidepressant efficacy, clinical safety, or an optimal therapeutic dose. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251273532; Idetifier: CRD420251273532.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.